A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is
A Bayesian Response-Adaptive Randomization Design for Clinical Trials with Survival Endpoints
Biometrics & Biostatistics International Journal
Accordingly to FDA draft guidance (2010), adaptive randomization (e.g. responseadaptive (RA) randomization) has become popular in clinical research because of its flexibility and efficiency, which also have the advantage of assigning fewer patients to inferior treatment arms. The RA design based on binary outcome is commonly used in clinical trial where "success" is defined as the desired (or undesired) event occurring within (or beyond) a clinical relevant time. As patients entering into trialdoi:10.15406/bbij.2016.03.00073 fatcat:526adyhlajdyfduiipvgwa626m